Structure Therapeutics (GPCR) EBIT (2022 - 2026)

Structure Therapeutics' EBIT history runs 5 years deep, the most recent figure standing at -$89.4 million for Q1 2026.

• On a quarterly basis, EBIT fell 58.72% year-over-year to -$89.4 million in Q1 2026; TTM through Mar 2026 was -$209.6 million, a 14.85% decrease from a year earlier, with the FY2025 full-year figure at -$176.6 million, down 11.59% from the prior year.
• EBIT retreated to -$89.4 million in Q1 2026 per GPCR's latest filing, from $24.0 million in the prior quarter.
• Across five years, EBIT topped out at $24.0 million in Q4 2025 and bottomed at -$89.4 million in Q1 2026.
• The 5-year median for EBIT is -$31.0 million (2023), against an average of -$34.1 million.
• Across the five-year window, EBIT tumbled 139.23% in 2023 and soared 150.97% in 2025, its largest moves.
• Year by year, EBIT stood at -$13.0 million in 2022, then tumbled by 139.23% to -$31.0 million in 2023, then slumped by 51.84% to -$47.1 million in 2024, then surged by 150.97% to $24.0 million in 2025, then sank by 472.58% to -$89.4 million in 2026.
• Per Business Quant, the three latest GPCR EBIT figures stand at -$89.4 million (Q1 2026), $24.0 million (Q4 2025), and -$73.8 million (Q3 2025).